GB2670416: A synthetic peptide formulation against melanoma and other cancers over-expressing S100B

Acces sibility Controls

The invention describes a novel bivalent helically constrained peptide targeted against S100B that is an effective anti-cancer drug against cancers that over-express S100B. This helix mimetic targeted against S100B induces rapid apoptosis in cancer cells that over-express a calcium binding protein S100B through simultaneous inhibition of key growth pathways including activation of p53.

Patent No:: GB2670416
Application No:: 12710321
Filing Date:: 30-07-2013
Issue Date:: 30-11-2016
Applicant:: CSIR-Indian Institute of Chemical Biology (CSIR-IICB), Kolkata
Inventor(s):: Amlanjyoti Dhar, Shampa Mallick, Israr Ahmed, Aditya Konar, Santu Bandyopadhyay, Siddhartha Roy
IPC Classification:: GB2670416
Country:: United Kingdom

Disclaimer: Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.

Acces sibility Controls

Patents